Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

(2012) P.N. Wiegand et al.   JOURNAL OF HOSPITAL INFECTION

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model

(2011) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model

(2009) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY